Based on BCR-ABL1 importance to the CML progress, targeted therapy with tyrosine kinase inhibitors (TKIs), such as imatinib, has been developed (Deininger et al., 2005; Shanmuganathan et al., 2017). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.